Leerink raises Doximity stock price target to $34 on valuation By Investing.com

Leerink raised Doximity’s price target to $34 from $31 while keeping an Outperform rating, but still expects fiscal 2027 guidance to come in below consensus amid slower growth and AI-related concerns. The firm cut its valuation multiple to about 13x calendar 2027 EBITDA and flagged competitive risks from OpenEvidence and large language model providers. The article also notes CFO Anna Bryson’s departure and recent mixed analyst actions, including downgrades from Truist and Evercore ISI.

Analysis

DOCS is in the classic post-multiple-reset phase where fundamentals can be merely “good enough” and the stock still struggles because the market is discounting a longer period of AI disruption risk. The key second-order effect is that any incremental spend on AI productization now behaves like a margin and FCF tax before it becomes a growth driver, so the stock may keep trading on forward skepticism until management shows measurable ROI conversion in customer expansion rather than just feature velocity. In that setup, valuation support matters less than the cadence of evidence; the catalyst is not a beat, but proof that AI is improving retention and monetization faster than competitive threats are eroding pricing power.

The competitive risk is asymmetric because AI-native niche entrants can attack the highest-velocity use cases first, while large model platforms can compress differentiation at the workflow layer. That means DOCS could face a slower, more subtle form of share loss: not obvious customer churn, but reduced expansion spend and lower attach rates, which would show up with a lag of 2-4 quarters in guidance quality. CFO turnover adds to that overhang because it increases the probability of a more conservative narrative around long-range targets, even if near-term operations remain intact.

The contrarian view is that the market may be overpricing the structural damage. If DOCS can demonstrate that AI is actually deepening product usage and shortening sales cycles, the multiple could re-rate quickly because the current setup has already embedded a lot of caution. The best trade window is likely after the next print: if guidance is trimmed but commentary proves customer ROI is real, the stock could rebound sharply as positioning is likely light and expectations are low.

Key Decisions for Investors

• Long DOCS only on a post-earnings flush into the $24-$26 area; target a move back to $31-$34 over 3-6 months if management shows AI monetization metrics and stable retention. Risk/reward improves only if the market gets a clearer downside reset first.
• Use a call spread in DOCS (e.g., 6-9 month $27.5/$35) to express upside from multiple recovery while capping premium at risk; this fits a scenario where fundamentals stabilize but valuation rerates slowly.
• Short DOCS against a basket of profitable healthcare software names if you want to isolate AI-disruption risk; the pair should work over 1-2 quarters if DOCS continues to lag on guidance credibility while peers show cleaner growth visibility.
• Avoid outright shorting DOCS into earnings unless you can tolerate squeeze risk; a low bar plus depressed sentiment creates asymmetric upside on even modestly better commentary.
• Set a catalyst watch for the next two quarters: if customer ROI data or AI adoption metrics do not improve, treat any rally toward the mid-$30s as an exit zone rather than a new compounding opportunity.